

Update: Systemic Diseases and the Cardiovascular System (IV)

Chemotherapy and the Heart

Juan C. Plana*

Section of Imaging, Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, Ohio, and Department of Cardiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Article history:

Available online 13 April 2011

Keywords:

Cardiotoxicity
Anthracyclins
Trastuzumab

Palabras clave:

Cardiotoxicidad
Antraciclínicas
Trastuzumab

ABSTRACT

The improvements in cancer detection and therapy have created a new cohort of patients who will experience sufficient survival to develop the cardiac complications of the cancer therapy. Three-dimensional echocardiography has been validated as the ultrasound modality with the best accuracy for the calculation of ejection fraction when compared to magnetic resonance imaging, the current gold standard, making it the tool of choice, when available, for the initial evaluation and follow up of the patient receiving chemotherapy.

If three-dimensional echocardiography is not available, or if the quality of the images is inadequate, the use of ultrasound contrast can be useful for the definition of the endocardial border and identification of the true apex of the heart, enhancing the ability of the interpreter to accurately calculate volumes and ejection fraction.

Two-dimensional strain appears promising as a tool to identify abnormalities in myocardial mechanics very early on during cardiotoxicity, allowing the prediction of later overt systolic dysfunction. This parameter may be useful in the detection of chemotherapy treated patients who could benefit from alternate therapies, thereby decreasing the incidence of cardiotoxicity and its associated morbidity and mortality.

© 2010 Sociedad Española de Cardiología. Published by Elsevier España, S.L. All rights reserved.

La quimioterapia y el corazón

RESUMEN

Las mejoras que se han producido en la detección y el tratamiento del cáncer han dado origen a una nueva cohorte de pacientes que alcanzan una supervivencia suficiente para que puedan aparecer complicaciones cardíacas derivadas del tratamiento del cáncer. La ecografía tridimensional ha sido validada como la modalidad ecográfica que aporta mayor exactitud al cálculo de la fracción de eyección, en comparación con la resonancia magnética, que es el patrón de referencia actual a este respecto, y ello hace que sea el método de elección para la evaluación inicial y el seguimiento de los pacientes tratados con quimioterapia.

Si no se dispone de ecocardiografía tridimensional o si la calidad de las imágenes es insuficiente, el uso de contraste ecográfico puede ser útil para definir el límite endocárdico e identificar el vértice cardíaco verdadero, con lo que se mejora la capacidad del evaluador para calcular con exactitud los volúmenes y la fracción de eyección.

El *strain* bidimensional parece prometedor como instrumento para identificar anomalías en la mecánica miocárdica en una fase muy temprana de la cardiotoxicidad y permite predecir una posterior disfunción sistólica manifiesta. Este parámetro puede ser útil en la detección de los pacientes tratados con quimioterapia que pueden obtener beneficio con el empleo de otra alternativa terapéutica, con lo que se reduciría la incidencia de la cardiotoxicidad y la morbimortalidad asociada a ella.

© 2010 Sociedad Española de Cardiología. Publicado por Elsevier España, S.L. Todos los derechos reservados.

INTRODUCTION

The treatment of cancer has progressed in a remarkable way over the last decade. The introduction of targeted therapies has increased the cure and remission rates in some cancers, and in others has converted cancer into a chronic disease. The net result

is an emerging cohort of patients who will have sufficient survival to experience the cardiac side effects of the therapies used to treat their neoplasias. Unfortunately, the abundant knowledge that has been collected on the biochemical pathways involved, and as a result targeted in the treatment of cancer, has not been paralleled by an understanding of the cardiac consequences of their modulation. This manuscript will use the treatment of breast cancer as a platform to illustrate the current understanding of the mechanisms of cardiotoxicity, the conventional methods for its evaluation, and the new strategies used for its early detection.

* Corresponding author: Section of Imaging, Department of Cardiovascular Medicine, The Cleveland Clinic, 9500 Euclid Avenue / J 1-5, Cleveland, Ohio 44195, United States.

E-mail address: planaj@ccf.org (J.C. Plana).

Abbreviations

CMR: cardiac magnetic resonance
 EF: ejection fraction
 LV: left ventricle
 LVEF: left ventricular ejection fraction
 RT3DE: real time three-dimensional echocardiography

BREAST CANCER: CHEMOTHERAPY AND CARDIOTOXICITY

Breast cancer is the most common cancer in women in the United States. The chance of developing invasive breast cancer during a woman's lifetime is approximately 1 in 7, with a mortality of about 1 in 33.¹ As the therapies and survival have improved, more than 2.2 million women are now breast cancer survivors in the United States.² The prolonged survival resulting from the cancer treatment allows patients to live long enough that cardiac toxicity can be the main determinant of quality of life, and in some cases of premature mortality.³ In fact, for early stage breast cancer, a patient is more likely to die from heart disease than from cancer.⁴ A number of therapies used in breast cancer are cardiotoxic⁵ (Table 1).

MECHANISMS OF TOXICITY

Anthracyclines

Anthracycline antibiotics have saved the lives of many cancer victims during the 50 years after their discovery. However, a major limitation of their use is the dose-limiting cardiotoxicity. Classically, our understanding of the mechanism of toxicity of anthracyclines has been focused on the role of the reactive oxygen species. More recently, this understanding has been expanded, involving the role of topoisomerase 2. There are two topoisomerase 2 isozymes in mammalian cells: Top2 α , and Top2 β .⁶ It is well established that the anti-tumor activity of doxorubicin is mediated by the formation of a Top2 α -doxorubicin-DNA ternary complex.⁷ The high efficacy of doxorubicin is thought to be due to the elevated expression of Top2 α in cancer cells. In contrast to Top2 α , which is only expressed in proliferating and tumor cells, Top 2 β is expressed in the adult heart. Lyu et al recently demonstrated that dexrazoxane antagonizes doxorubicin-induced DNA damage through its interference with Top2 β , which could implicate Top2 β in doxorubicin cardiotoxicity.⁸ The cardiotoxicity of anthracyclines, a mainstay of breast cancer treatment, is well

Table 1
Toxicity of Chemotherapeutic Agents

Agent	Most frequent toxicity
Fluoracil	Myocardial ischemia and infarction
Anthracyclines	Cardiomyopathy, myopericarditis, arrhythmias
Cisplatin	Hypertension
Cyclophosphamide	Heart failure, myopericarditis, arrhythmias
Taxanes	Heart failure, ischemia, arrhythmias
Methotrexate	Ischemia, arrhythmias
Trastuzumab	Heart failure
Tamoxifen	Venous thrombosis
Radiotherapy	Restrictive heart disease, accelerated atherosclerosis, pericardial effusion

known, with a reported overall incidence of symptomatic heart failure between 2.2% and 5.1%.⁹ The curves drawn by Von Hoff, and from our experience at MD Anderson, appeared flat as long as the patient received a dose lower than 450 mg/m². As a result, physicians felt safe administering doses lower than 450 /m². However, recent data from an animal model indicates that the toxicity is not as previously thought. Neilan et al developed an acute and a chronic model of toxicity. In the acute model, there was minimal detectable apoptosis at baseline. However, there was evidence of a 75-fold increase in cardiac cell apoptosis just 24 h after a single injection of 20 mg/kg of doxorubicin.¹⁰ The current understanding of anthracycline-induced cardiomyopathy involves a dose-dependant loss of cardiac myocytes secondary to apoptosis and necrosis. Following the biomechanical model of heart failure, the ejection fraction (EF) falls as a result of the remodeling of the left ventricle (LV).

Anthracycline-induced cardiomyopathy has been associated with a particularly poor prognosis, with 2-year mortality of up to 60%.¹¹

Trastuzumab

The amplification of the HER2/neu (ErbB2) gene represents a pivotal modification in a subgroup of very aggressive breast cancer. Trastuzumab (Herceptin[®]) is a humanized monoclonal antibody against the HER2 protein. The development of this antibody as adjuvant therapy for early HER2-positive breast cancers ranks as one of the most satisfying and powerful examples of translational medicine to date. A series of large-scale studies has conclusively shown that trastuzumab can substantially reduce the risk of recurrence and early death in women with HER2-positive breast cancers. Heart failure, a serious side effect of trastuzumab, occurs in up to 4% of patients treated with the antibody. Ten percent of patients have a drop in cardiac function.¹²

Combination Chemotherapy

Trastuzumab increases the cardiotoxicity of anthracyclines. LV dysfunction is noted in 19%-32% of patients in studies administering trastuzumab after anthracycline-based chemotherapy.¹³ Studies of mutant mouse models have documented an essential role of the *ErbB2* gene in the embryonic and postnatal heart. The induction of cardiac stress pathways, by either hemodynamic overload or the cardiotoxicity of anthracyclines, promotes the onset of left ventricular dysfunction in mice that are deficient in ErbB2 protein. The basis for the toxicity is the fundamental role of the ErbB2-ErbB4 heterodimeric receptors in triggering the myocyte-survival pathways required during the activation of acute stress signals. The loss of the survival cues after trastuzumab treatment can lead to irreversible loss of cardiac myocytes during exposure to the anthracyclines. This reasoning is consistent with the clinical finding that trastuzumab also increases the risk of cardiac side effects in patients with existing forms of heart disease in which the cardiac stress signals are presumably already activated.¹²

EVALUATION OF CARDIAC TOXICITY SECONDARY TO CHEMOTHERAPY

Left ventricular ejection fraction (LVEF) is a robust predictor of outcome, and the variable used historically to evaluate cardiac systolic function at baseline and during chemotherapy. The evaluation of LVEF is commonly done through echocardiography or multiple gated acquisition (MUGA) scan.¹⁴

Two-Dimensional Echocardiography

Echocardiography has the advantage of being a non-invasive method that does not involve the use of radiation. In addition to reporting the EF, it provides other information on cardiac morphology, chamber size, and valvular and diastolic function.¹⁵ However, the measurement of LVEF presents a number of challenges related to image quality, assumption of left ventricular geometry, load dependency, and expertise.¹⁶ As a result, the 95% confidence intervals of measured LVEF are $\pm 11\%$, failing to detect subtle alterations in LV function. In addition, the inter and intra-observer variability is higher than in MUGA scan (8.8% vs. 6.8% for two-dimensional echocardiography).¹⁷

Multiple Gated Acquisition Scan

The measurement of LVEF using MUGA scan has the advantage of lower inter-observer variability ($< 5\%$ ¹⁸) and the lack of geometrical modeling. Disadvantages of MUGA include the exposure to radioactivity and the limited information that can be obtained on cardiac structure and diastolic function.

Magnetic Resonance Imaging

Cardiac magnetic resonance (CMR) is considered the gold standard for the evaluation of left ventricular volumes, mass, and EF. Its high reproducibility, the lack of geometrical assumptions, and the ease of demarcation of the endocardium from the trabeculation make this technique particularly appealing for the evaluation of LV function. However, its lack of availability and high cost limit its routine use.¹⁵

ASSESSMENT OF CARDIOTOXICITY IN THE ECHO LAB

The sequential monitoring of cardiac function during chemotherapy is of paramount importance to early detection of LV dysfunction. Currently, there are guidelines for monitoring chemotherapy-induced cardiotoxicity in children treated with anthracyclines.¹⁹ In the adult population, the American Heart Association recommends close monitoring of cardiac function during anthracycline therapy, although it does not specify the methods, thresholds, or intervals that should be utilized during follow-up.²⁰ For patients treated with anthracyclines, echocardiography has been the preferred method of monitoring cardiac function.^{21–25}

Definition of Cardiotoxicity

Cardiotoxicity has been defined using various classifications. Recent guidelines suggest that a reduction of LVEF $>5\%$ to LVEF $<55\%$ with symptoms of heart failure, or an asymptomatic reduction of LVEF of $>10\%$ to a LVEF $<55\%$, constitute cardiotoxicity.²⁶

Although LVEF is the most commonly monitored parameter during chemotherapy, its prognostic value in this particular population appears still controversial. In a study of 28 patients with non-Hodgkin lymphoma receiving doxorubicin, Nousiainen et al.²⁷ reported a significant decline of LVEF at low cumulative doses that was predictive of later development of cardiotoxicity. In contrast, in a study of 120 patients with breast cancer followed before, during, and 3 years after treatment with epirubicin, monitoring of LVEF did not seem to correlate with later development of cardiotoxicity.²⁸ However, Alexander et al.²⁹

demonstrated its usefulness in the sequential evaluation of LVEF in clinical practice.

Improved Measurements of Left Ventricular Ejection Fraction With Novel Technology

Newer technology has emerged that allows for an improvement in the accuracy of calculating EF.

Contrast Echocardiography

Contrast echocardiography defines the endocardial border better than unenhanced echocardiography and, compared with unenhanced echocardiography in numerous single center and multicenter studies, shows better agreement and reduction in intra-observer and inter-observer variabilities in measured LV volumes and LVEF, with the use of current reference standards. The American Society of Echocardiography guidelines state that the underestimation of cardiac volumes by echocardiography can be nearly resolved when contrast agents are used.³⁰

Three-Dimensional Echocardiography

The calculation of EF using 2D echocardiography has important limitations, based on geometrical models that do not take into consideration the architecture of the sick heart, and that are strongly affected by foreshortening. Real time three-dimensional echocardiography (RT3DE) has emerged as a solution to these problems. The ability to capture a full volume acquisition of the LV allows for accurate identification of the true apex of the heart. An algorithm based on the detection of the endocardial border then allows for direct quantification of LV volumes, without multiplane tracing or geometric modeling.

Jacobs et al. compared two-dimensional and three-dimensional echocardiography against CMR imaging for their ability to accurately calculate the end diastolic volume (EDV), end systolic volume (ESV), and EF. The RT3DE measurements of LV volumes correlated highly with CMR imaging values ($r=0.96$, $r=0.97$ and $r=0.93$ for EDV, ESV, and EF, respectively)³¹ (Fig. 1). The LV volume assessment and calculation of EF by RT3DE is a rapid, accurate and reproducible method, superior to conventional 2D methods. The small negative biases of the calculation of volumes and EF, as compared to CMR, should be reduced as we gain experience with this new technique, and as we learn to trace the endocardium underneath the trabeculations, and not on top of them.³²

Contrast-Enhanced Three-Dimensional Echocardiography

More recently, contrast has been used to enhance RT3DE images. Contrast enhancement was found not only to improve the accuracy and reproducibility of LV volume measurements in patients with poor image quality, but also to enhance the assessment of regional wall motion from RT3DE datasets. With the use of selective dual triggering to minimize bubble destruction by ultrasound energy, contrast enhancement increased the accuracy of RT3DE-based analysis of regional LV function against CMR reference, and improved its reproducibility to levels similar to those noted in patients with optimal imaging quality.³³

Implications of a More Accurate Ejection Fraction

The improved accuracy and reproducibility of RT3DE-based LV volumes and LVEF measurements are of vital importance in the




Figure 1. Calculation of left ventricular volumes and ejection fraction using three-dimensional echocardiography. A: End diastolic frame. B: End systolic frame.

patient receiving chemotherapy, since clinical decision making relies completely on this measurement. In the study mentioned above by Jacobs, there was evidence of a wider limit of agreement for EDV, ESV and EF for two-dimensional transthoracic echocardiography (2DTTE) (29%, 24% and 9.5%, respectively) compared to RT3DE (17%, 6% and 6.4%).³¹ This means that when using 2DTTE, the EF can potentially be miscalculated by 9.5 points.

Anthracyclines are discontinued if patients have a symptomatic drop of more than 5% of their EF, to below 55%, or an asymptomatic drop of more than 10% of their initial EF. Miscalculation of the EF by 2DTTE can lead to a decision by the oncologist to stop the anthracycline-based regimen due to concern for toxicity, in a patient that actually doesn't have it, where the mistake in the calculation of EF is solely the result of the inherent limitations of the technology used.

Diastole and Cardiotoxicity

In chemotherapy-induced cardiotoxicity as in other cardiac conditions (such as ischemic cardiomyopathy^{34–37}), alterations in diastolic dysfunction may precede the systolic dysfunction. The abnormalities of the diastolic parameters seem to represent an early sign of LV dysfunction in patients treated with chemotherapy.^{38–40} In a study of 26 patients with acute leukemia treated with

2–6 cycles of anthracycline-based chemotherapy, the changes in diastolic function developed very early on, after the initiation of chemotherapy, with significant reduction in the E/A ratio and prolongation of both deceleration and of isovolumetric relaxation time before LVEF decreased.⁴¹ Stoddard et al.⁴² prospectively evaluated 26 patients before beginning chemotherapy (doxorubicin) and 3 weeks after cumulative doses. He observed prolongation of the isovolumetric relaxation time preceding a significant decrease in LVEF. These studies reinforce the predictive value of the diastolic indices for the development of subsequent cardiotoxicity.

Stress Echocardiography and Cardiotoxicity

Exercise and pharmacologic stress testing has been studied as a way to unmask subclinical LV dysfunction. In 31 cancer patients studied before, during, and 6 months after chemotherapy, low-dose dobutamine did not provide additional value for the early detection of cardiotoxicity.^{43,44} However, in 26 patients treated with high-dose anthracyclines and without symptoms of cardiac dysfunction, high-dose dobutamine revealed an alteration of the fractional shortening and the transmitral E/A ratio.⁴⁵ Exercise echocardiography can unmask subclinical cardiac dysfunction, as demonstrated by Jarfelt et al.⁴⁶ in 23 young adults. These patients




Figure 2. Two-dimensional-based strain of a patient with anthracycline-induced cardiomyopathy. The mid and apical segments of the anterior wall exhibit abnormal regional strain.

were acute lymphoblastic leukemia survivors who had received anthracyclines before the onset of puberty and were followed for a median of 21 years after remission. Ten of the 23 patients presented with reduced LVEF at stress; reduced LVEF was not observed in any of the controls.

Two-Dimensional Based Strain

Two-dimensional strain (2DS) is an automated quantitative technique for the measurement of global long-axis function from gray-scale images. Longitudinal tissue deformation is evaluated by frame-by-frame tracking of individual speckles throughout the cardiac cycle (Figs. 2 and 3). Global longitudinal strain (GLS) is calculated from the mean of 18 cardiac segments. The 2DS technique is more robust than tissue-Doppler-derived strain, does not suffer from angle dependency, and is easier to calculate. The following studies provide evidence for the superiority of 2D-based strain as compared to EF for the evaluation of the chemotherapy patient.

1. *Strain Versus Ejection Fraction in the Prognosis of All Cause Mortality in the General Population.* Stanton et al. recently published a study comparing GLS against EF for the prediction of all cause mortality in the general population. He concludes that GLS is superior to either EF or wall motion score index as a predictor of outcome and may become the optimal method of assessment of global LV function.¹⁶
2. *Strain as a New Prognosticator in Acute Heart Failure.* The study published by Cho et al. concludes that strain is a powerful predictor of cardiac events and appears to be a better parameter than EF in the evaluation of patients with acute heart failure.⁴⁷
3. *Reliability of the Technique.* Marwick et al. published a brief report on normal GLS values and their reliability, evaluating 242 patients. Inter-observer variability (comparison between sites) was measured in 253 segments. The mean difference in measurements was 0.24 percentage points. A total of 38 patients underwent successive tests within 1 h; the test-retest variability showed no systematic bias, and 95% confidence intervals were between -9.6% and +9.7%.⁴⁸

4. *Strain Rate and Early Detection of Cardiotoxicity.* Marwick sought to determine whether changes in tissue deformation, assessed by myocardial strain and strain rate [SR], were able to identify LV dysfunction earlier than conventional echocardiographic measures in patients treated with trastuzumab. Study of 152 sequential echocardiograms in 35 female patients showed significant reductions seen in tissue Doppler imaging strain rate ($P < .05$), 2D-SR ($P < .001$) and 2D radial SR ($P < .001$). Of the 18 patients with reduced longitudinal SR, 3 had a concurrent reduction in EF $\geq 10\%$ and another 2 showed a reduction over 20 months follow-up.⁴⁹
5. *Global Longitudinal Strain and Early Detection of Cardiotoxicity.* In this second study, our group, in collaboration with the echocardiography laboratory at Massachusetts General Hospital and others, sought to evaluate whether sensitive echocardiographic measurements and biomarkers could predict later cardiac dysfunction in 43 chemotherapy-treated patients.




Figure 3. Polar map of the patient with anthracycline-induced cardiomyopathy referenced in Figure 2.

Measurements included LVEF peak systolic myocardial longitudinal and radial strain, echocardiographic markers of diastolic function, N-terminal pro-brain natriuretic peptide (NT-proBNP), and cardiac troponin I (cTnI). Nine patients (21%) developed cardiotoxicity (1 at 3 months and 8 at 6 months). The decrease in longitudinal strain from baseline to 3 months and a detectable troponin at 3 months were independent predictors of the development of cardiotoxicity at 6 months. Left ventricular EF, parameters of diastolic function, and NT-proBNP did not predict cardiotoxicity.⁵⁰

6. **Radial Strain.** Recently, Jurcutt et al.⁵¹ demonstrated that myocardial deformation parameters, which included longitudinal and radial strain and strain rate, allowed detecting subtle alterations in longitudinal and radial LV function following 6 cycles of pegylated liposomal doxorubicin in 16 elderly women with breast cancer. The LV dimensions, EF, and systolic myocardial velocity did not change during the follow-up.

The author postulated that an abnormality in radial strain could be the earliest manifestation of toxicity expressed in the population studied.

CONFLICTS OF INTEREST

Dr. Plana has received clinical research support from General Electric and participated in educational activities sponsored by this company.

REFERENCES

1. National Cancer Institute. SEER Cancer Statistics Review 1975–2007. Available at: http://seer.cancer.gov/csr/1975_2007/index.html
2. Cancer survivorship –United States, 1971–2001. *MMWR Morb Mortal Wkly Rep.* 2004;53:526–9.
3. Mann DL, Krone RJ. Cardiac disease in cancer patients: An overview. *Prog Cardiovasc Dis.* 2010;53:80–7.
4. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, et al. Overall survival and cause-specific mortality of patients with stage t1a,bn0m0 breast carcinoma. *J Clin Oncol.* 2007;25:4952–60.
5. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer therapy and cardiovascular injury. *J Am Coll Cardiol.* 2007;50:1435–41.
6. Wang JC. Cellular roles of DNA topoisomerases: A molecular perspective. *Nat Rev Mol Cell Biol.* 2002;3:430–40.
7. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. *Science.* 1984;226:466–8.
8. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, et al. Topoisomerase II β -mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. *Science.* 2007;67:8839–46.
9. Von Hoff DD, Layard MW, Basa P, Davis Jr HL, Von Hoff AL, Rozenzweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. *Ann Intern Med.* 1979;91:710–7.
10. Neilan TG, Jassal DS, Pérez-Sanz TM, Raheer MJ, Pradhan AD, Buys ES, et al. Tissue doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. *Eur Heart J.* 2006;27:1868–75.
11. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. *N Engl J Med.* 2000;342:1077–84.
12. Chien KR. Herceptin and the heart—a molecular modifier of cardiac failure. *N Engl J Med.* 2006;354:789–90.
13. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses her2. *N Engl J Med.* 2001;344:783–92.
14. Jannazzo A, Hoffman J, Lutz M. Monitoring of anthracycline-induced cardiotoxicity. *Ann Pharmacother.* 2008;42:99–104.
15. Jurcutt R, Wildiers H, Ganame J, D'Hooge J, Paridaens R, Voigt JU. Detection and monitoring of cardiotoxicity—what does modern cardiology offer? *Support Care Cancer.* 2008;16:437–45.
16. Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain; comparison with ejection fraction and wall motion scoring index. *Circ Cardiovasc imaging.* 2009;2:356–64.
17. Chuang ML, Hibberd MG, Salton CJ, Beaudin RA, Riley MF, Parker RA, et al. Importance of imaging method over imaging modality in noninvasive determination of left ventricular volumes and ejection fraction: Assessment by two- and three-dimensional echocardiography and magnetic resonance imaging. *J Am Coll Cardiol.* 2000;35:477–84.
18. Skrypnik JV, Bailey D, Cosgriff PS, Fleming JS, Houston AS, Jarritt PH, et al. UK audit of left ventricular ejection fraction estimation from equilibrium ecg gated blood pool images. *Nucl Med Commun.* 2005;26:205–15.
19. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the cardiology committee of the childrens cancer study group. *Pediatrics.* 1992;89:942–9.
20. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. *Circulation.* 2005;112:e154–e235.
21. Schwartz RG, McKenzie WB, Alexander J, Sager P, D'Souza A, Manatunga A, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiography. *Am J Med.* 1987;82:1109–18.
22. Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. *Semin Oncol.* 2006;33:2–14.
23. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. *J Clin Oncol.* 1997;15:1318–32.
24. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. *J Clin Oncol.* 2001;19:1444–54.
25. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. *Cancer.* 2002;94:25–36.
26. Seidman AD, Fornier MN, Esteve FJ, Tan L, Kaptain S, Bach A, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by her2 immunophenotype and gene amplification. *J Clin Oncol.* 2001;19:2587–95.
27. Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. *Br J Cancer.* 2002;86:1697–700.
28. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, long-term observational study of outcome in 120 patients. *Ann Oncol.* 2002;13:699–709.
29. Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiography. *N Engl J Med.* 1979;300:278–83.
30. Mulvagh SL, Rakowski H, Vannan MA, Abdelmoneim SS, Becher H, Bierig SM, et al. American Society of Echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography. *J Am Soc Echocardiogr.* 2008;21:1179–201.
31. Jacobs LD, Salgo IS, Goonewardena S, Weinert L, Coon P, Bardo D, et al. Rapid online quantification of left ventricular volume from real-time three-dimensional echocardiographic data. *Eur Heart J.* 2006;27:460–8.
32. Mor-Avi V, Sugeng L, Lang RM. Real-time 3-dimensional echocardiography: An integral component of the routine echocardiographic examination in adult patients? *Circulation.* 2009;119:314–29.
33. Corsi C, Coon P, Goonewardena S, Weinert L, Sugeng L, Polonsky TS, et al. Quantification of regional left ventricular wall motion from real-time 3-dimensional echocardiography in patients with poor acoustic windows: Effects of contrast enhancement tested against cardiac magnetic resonance. *J Am Soc Echocardiogr.* 2006;19:886–93.
34. Moller JE, Sondergaard E, Poulsen SH, Egstrup K. Pseudonormal and restrictive filling patterns predict left ventricular dilation and cardiac death after a first myocardial infarction: A serial color m-mode doppler echocardiographic study. *J Am Coll Cardiol.* 2000;36:1841–6.
35. Moller JE, Pellikka PA, Hillis GS, Oh JK. Prognostic importance of diastolic function and filling pressure in patients with acute myocardial infarction. *Circulation.* 2006;114:438–44.
36. Moller JE, Whalley GA, Dini FL, Doughty RN, Gamble GD, Klein AL, et al. Independent prognostic importance of a restrictive left ventricular filling pattern after myocardial infarction: An individual patient meta-analysis: Meta-analysis research group in echocardiography acute myocardial infarction. *Circulation.* 2008;117:2591–8.
37. Nijland F, Kamp O, Karreman AJ, Van Eenige MJ, Visser CA. Prognostic implications of restrictive left ventricular filling in acute myocardial infarction: A serial Doppler echocardiographic study. *J Am Coll Cardiol.* 1997;30:1618–24.
38. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. *Circulation.* 2004;109:3122–31.
39. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle. *N Engl J Med.* 2004;350:1953–9.

40. Marchandise B, Schroeder E, Bosly A, Doyen C, Weynants P, Kremer R, et al. Early detection of doxorubicin cardiotoxicity: Interest of doppler echocardiographic analysis of left ventricular filling dynamics. *Am Heart J*. 1989;118:92–8.
41. Pudil R, Horacek JM, Strasova A, Jebavy L, Vojacek J. Monitoring of the very early changes of left ventricular diastolic function in patients with acute leukemia treated with anthracyclines. *Exp Oncol*. 2008;30:160–2.
42. Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. *J Am Coll Cardiol*. 1992;20:62–9.
43. Bountioukos M, Doorduyn JK, Roelandt JR, Vourvouri EC, Bax JJ, Schinkel AF, et al. Repetitive dobutamine stress echocardiography for the prediction of anthracycline cardiotoxicity. *Eur J Echocardiogr*. 2003;4:300–5.
44. Cottin Y, L'Huillier I, Casasnovas O, Geoffroy C, Caillot D, Zeller M, et al. Dobutamine stress echocardiography identifies anthracycline cardiotoxicity. *Eur J Echocardiogr*. 2000;1:180–3.
45. Hamada H, Ohkubo T, Maeda M, Ogawa S. Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer. *Pediatr Int*. 2006;48:313–20.
46. Jarfelt M, Kujacic V, Holmgren D, Bjarnason R, Lannering B. Exercise echocardiography reveals subclinical cardiac dysfunction in young adult survivors of childhood acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2007;49:835–40.
47. Cho GY, Marwick TH, Kim HS, Kim MK, Hong KS, Oh DJ. Global 2-dimensional strain as a new prognosticator in patients with heart failure. *J Am Coll Cardiol*. 2009;54:618–24.
48. Marwick TH, Leano RL, Brown J, Sun JP, Hoffmann R, Lysyansky P, et al. Myocardial strain measurement with 2-dimensional speckle-tracking echocardiography: Definition of normal range. *JACC Cardiovasc Imaging*. 2009;2:80–4.
49. Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. *Am Heart J*. 2009;158:294–301.
50. Sawaya HSI, Plana JC, Januzzi JL, Ky B, Cohen V, Carver J, et al. Early detection and prediction of cardiotoxicity in chemotherapy treated patients; an echocardiographic and biomarker study. American Society of Echocardiography 2010 Scientific Sessions; June 13, 2010; San Diego, CA. Abstract P1–42. Available at: <http://www.asecho.org/files/EAC2010.PDF>
51. Jurcut R, Wildiers H, Ganame J, D'Hooge J, De Backer J, Denys H, et al. Strain rate imaging detects early cardiac effects of pegylated liposomal doxorubicin as adjuvant therapy in elderly patients with breast cancer. *J Am Soc Echocardiogr*. 2008;21:1283–9.